Get the Stockscreener App
5.20
2.44%
-0.13
After Hours:
5.30
0.10
+1.92%
Verrica Pharmaceuticals Inc stock is traded at $5.20, with a volume of 58,847.
It is down -2.44% in the last 24 hours and down -21.33% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$5.33
Open:
$5.21
24h Volume:
58,847
Relative Volume:
0.27
Market Cap:
$83.15M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-3.5374
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-4.94%
1M Performance:
-21.33%
6M Performance:
+1.86%
1Y Performance:
-17.00%
1-Day Range:
$5.06
$5.3909
1-Week Range:
$5.00
$5.68
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.20 | 85.23M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Bitget
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: How does Verrica Pharmaceuticals Inc score in quality rankingsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - Yahoo Finance
Watch Verrica's CEO speak live from TD Cowen's Boston healthcare conference - Stock Titan
How does Verrica Pharmaceuticals Inc. perform in inflationary periodsExit Point & Smart Allocation Stock Tips - mfd.ru
Verrica Pharmaceuticals: Strategic Execution Takes Center Stage - AD HOC NEWS
West Chester-Based Verrica Partner Launches YCANTH in Japan - MyChesCo
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - MyChesCo
Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical - Intellectia AI
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
What’s the outlook for Verrica Pharmaceuticals Inc.’s sector2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Appoints Chris Chapman As Chief Commercial Officer - TradingView
Verrica’s Japanese Market Debut: A Strategic Expansion Unfolds - AD HOC NEWS
Verrica’s partner launches molluscum treatment in Japan By Investing.com - Investing.com Australia
Verrica’s partner launches molluscum treatment in Japan - Investing.com Nigeria
Verrica announces launch of Ycanth in Japan by Torii - The Pharma Letter
Verrica Pharmaceuticals Announces Launch Of Ycanth® For The Treatment Of Molluscum Contagiosum In Japan - TradingView
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan - Investing.com Nigeria
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - The Manila Times
Verrica Pharmaceuticals Announces Launch of YCANTH® for the - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
ETF Watch: Can Verrica Pharmaceuticals Inc continue delivering strong returnsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Verrica Pharmaceuticals (VRCA) upgraded to strong buy: Here's why - MSN
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - sharewise.com
Institution Moves: What hedge funds are buying Verrica Pharmaceuticals IncTrade Exit Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rally Mode: What is the PEG ratio of Intellicheck Inc2025 Fundamental Recap & Smart Allocation Stock Reports - baoquankhu1.vn
Sovran Advisors LLC Trims Holdings in Verrica Pharmaceuticals Inc. $VRCA - MarketBeat
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Portfolio Recap: How does KeyCorp perform in inflationary periodsEarnings Trend Report & AI Powered Market Trend Analysis - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint - TipRanks
Verrica’s VP-102 Advances Dermatology Care: First Patient Dosed in Global Phase 3 Common Warts Program - Barchart.com
Aug PreEarnings: Is Verrica Pharmaceuticals Inc stock a value trapMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):